Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

137 enrolled 31 charts

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT05733351 2025-09-15

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Phase 1 Terminated

4 enrolled

Genitourinary

Prostatic Neoplasms

NCT05204927 2025-07-31

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Phase 3 Active not recruiting

439 enrolled

Genitourinary

Prostatic Neoplasms

NCT05177042 2025-07-25

Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 1 Completed

45 enrolled

Genitourinary

Prostatic Neoplasms

NCT05288166 2025-06-27

CYCLONE 3

Phase 3 Active not recruiting

925 enrolled 12 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT03072238 2025-06-06

IPATential150

Phase 3 Completed

1,101 enrolled 35 charts

Genitourinary

Prostatic Neoplasms

NCT01848067 2025-05-04

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Phase 1/2 Completed

9 enrolled 9 charts

Genitourinary

Prostatic Neoplasms

NCT04262154 2025-04-27

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Phase 2 Active not recruiting

28 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

AcTFirst

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

rechARge

AASUR in High Risk Prostate Cancer

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

uPARCRPC

TRIPLE-SWITCH

SPLASH

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

DIVINE

CONTACT-02

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Abiraterone Acetate for Castrate Resistant Prostate Cancer

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

CYCLONE 3

IPATential150

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer